Covered recipient · General Payments record
RICHARD M GLOVER
Allopathic & Osteopathic Physicians Family Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2022 · Entire year
$1,870.35
159 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2022 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,870.35 | 159 |
By paying entity
PY2022 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $493.01 | 42 |
| Biohaven Pharmaceutical Holding Company Ltd. | $224.80 | 17 |
| Lilly USA, LLC | $209.01 | 23 |
| PFIZER INC. | $150.15 | 10 |
| Novo Nordisk Inc | $148.10 | 18 |
| Amgen Inc. | $137.43 | 10 |
| Bayer HealthCare Pharmaceuticals Inc. | $130.98 | 15 |
| Sunovion Pharmaceuticals Inc. | $87.83 | 6 |
| AstraZeneca Pharmaceuticals LP | $37.43 | 3 |
| Merck Sharp & Dohme LLC | $36.00 | 2 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $31.17 | 2 |
| Daiichi Sankyo Inc. | $31.05 | 2 |
| Abbott Laboratories | $29.08 | 2 |
| UPSHER-SMITH LABORATORIES LLC | $23.90 | 1 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $22.62 | 1 |
| GlaxoSmithKline, LLC. | $19.52 | 1 |
| Janssen Pharmaceuticals, Inc | $17.08 | 1 |
| Almatica Pharma LLC | $16.13 | 1 |
| Teva Pharmaceuticals USA, Inc. | $13.30 | 1 |
| SANOFI-AVENTIS U.S. LLC | $11.76 | 1 |
Page 4 of 4; records 151–159 of 159 matching records. This page contains 9 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
RICHARD M GLOVER
NPI 1063480937 · CMS profile ID 48347
Allopathic & Osteopathic Physicians / Family Medicine
NEWTON, KS
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 4 of 4; records 151–159 of 159 matching records. This page contains 9 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1063480937?year=2022&recipient=provider&page=4#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- RICHARD M GLOVER, NPI 1063480937, CMS profile ID 48347. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–159 of 159 matching records. This page contains 9 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1063480937?year=2022&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- APA 7
- IndustryPayments. (2026). RICHARD M GLOVER, NPI 1063480937, CMS profile ID 48347. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–159 of 159 matching records. This page contains 9 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1063480937?year=2022&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- Bluebook
- RICHARD M GLOVER, NPI 1063480937, CMS profile ID 48347, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–159 of 159 matching records. This page contains 9 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1063480937?year=2022&recipient=provider&page=4#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30
159 matching records · $1,870.35 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 151–159 of 159.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Bayer HealthCare Pharmaceuticals Inc. | $6.30 | 01/24/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 929907541 | CMS |
| ABBVIE INC. | $13.57 | 01/19/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891043087 | CMS |
| Abbott Laboratories | $13.08 | 01/18/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 920403705 | CMS |
| Novo Nordisk Inc | $9.67 | 01/14/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 899561109 | CMS |
| Teva Pharmaceuticals USA, Inc. | $13.30 | 01/13/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 954639317 | CMS |
| UPSHER-SMITH LABORATORIES LLC | $23.90 | 01/13/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 912294311 | CMS |
| Amgen Inc. | $16.97 | 01/12/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939372313 | CMS |
| Amgen Inc. | $6.02 | 01/11/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939372305 | CMS |
| Daiichi Sankyo Inc. | $15.60 | 01/05/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 930799769 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $783,129.09 | 107 |
| PY2024 | Recipient | $12,977.61 | 1 |
| PY2024 | Principal investigator | $1,043,028.66 | 73 |
| PY2023 | Recipient | $620.01 | 1 |
| PY2023 | Principal investigator | $2,541,504.79 | 689 |
| PY2022 | Recipient | $35,758.66 | 6 |
| PY2022 | Principal investigator | $6,784,890.70 | 1,814 |
| PY2021 | Principal investigator | $6,776,236.49 | 415 |
| PY2020 | Recipient | $236.50 | 1 |
| PY2020 | Principal investigator | $965,254.86 | 71 |
| PY2019 | Recipient | $705.39 | 1 |
| PY2019 | Principal investigator | $728,930.78 | 104 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
107 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $600.00 | 12/31/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Ubrogepant for the Preventive Treatment of Menstrual Migraine with an Open-Label Extension | No dispute reported | 06/30/2026 | 1202533461 |
| Principal investigator 1 | ABBVIE INC. | $2,107.00 | 12/30/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202532190 |
| Principal investigator 1 | PFIZER INC. | $23,950.00 | 12/27/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research LLC | A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228751181 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/23/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228725054 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/23/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228725056 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/23/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228725174 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/23/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228725176 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/23/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228725486 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/23/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228726098 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/23/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228726358 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/23/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228731280 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/23/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228731379 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/23/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228731569 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/23/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228733247 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/23/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228734899 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/23/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228735377 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/23/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228735430 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/23/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228735765 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/23/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228735769 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/23/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228736080 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/23/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228736117 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/23/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228736261 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/23/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228738863 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/22/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228725290 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/22/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228725484 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/22/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228725686 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/22/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228725922 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/22/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228725924 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/22/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228726356 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/22/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228731275 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/22/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228731964 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/22/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228733225 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/22/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228733477 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/22/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228735058 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/22/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228735283 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/22/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228735380 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/22/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228735384 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/22/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228735920 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/22/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228736121 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/22/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228736285 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/22/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228736513 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/22/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228736641 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/22/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228738454 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $10,150.00 | 12/18/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research Llc | A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). | No dispute reported | 06/30/2026 | 1226107729 |
| Principal investigator 1 | PFIZER INC. | $909.00 | 12/10/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228728005 |
| Principal investigator 1 | PFIZER INC. | $1,404.00 | 12/10/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228729233 |
| Principal investigator 1 | ABBVIE INC. | $4,000.00 | 11/28/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202526112 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 11/25/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228725052 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 11/25/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228725172 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 11/25/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228725336 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 11/25/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228731539 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 11/25/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228731573 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 11/25/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228732687 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 11/25/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228733258 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 11/25/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228733480 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 11/25/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228735916 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 11/25/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228736165 |
| Principal investigator 1 | ABBVIE INC. | $4,000.00 | 11/20/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202524836 |
| Principal investigator 1 | Bavarian Nordic A/S | $1,564.27 | 11/19/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214746 |
| Principal investigator 1 | PFIZER INC. | $180.80 | 11/18/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228723422 |
| Principal investigator 1 | PFIZER INC. | $265.20 | 11/18/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228724482 |
| Principal investigator 1 | PFIZER INC. | $180.80 | 11/18/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228729236 |
| Principal investigator 1 | PFIZER INC. | $265.20 | 11/18/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228729354 |
| Principal investigator 1 | Bavarian Nordic A/S | $1,134.47 | 11/07/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214748 |
| Principal investigator 1 | ABBVIE INC. | $3,516.32 | 11/05/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202522125 |
| Principal investigator 1 | ABBVIE INC. | $7,841.30 | 10/09/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202515529 |
| Principal investigator 1 | Bavarian Nordic A/S | $6.75 | 10/03/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214732 |
| Principal investigator 1 | Bavarian Nordic A/S | $743.60 | 10/01/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214730 |
| Principal investigator 1 | Bavarian Nordic A/S | $3,703.55 | 08/27/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214714 |
| Principal investigator 1 | Bavarian Nordic A/S | $152.00 | 08/27/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214724 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $12,634.70 | 08/13/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH | A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS | No dispute reported | 06/30/2026 | 1185540681 |
| Principal investigator 1 | ABBVIE INC. | $1,500.00 | 07/24/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202499672 |
| Principal investigator 1 | ABBVIE INC. | $6,028.60 | 07/02/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202496567 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,500.00 | 07/02/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research, LLC, Knoxville | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215517900 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,050.00 | 07/02/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research, LLC, Knoxville | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215517903 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,900.00 | 07/02/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research, LLC, Knoxville | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215517908 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,500.00 | 07/02/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research, LLC, Knoxville | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215517912 |
| Principal investigator 1 | Eli Lilly and Company | $730.00 | 06/23/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) | No dispute reported | 06/30/2026 | 1187880541 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $791.00 | 06/09/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research,llc | A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). | No dispute reported | 06/30/2026 | 1226113048 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $336.00 | 06/09/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research,llc | A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). | No dispute reported | 06/30/2026 | 1226113050 |
| Principal investigator 1 | Bavarian Nordic A/S | $9,982.58 | 06/04/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214662 |
| Principal investigator 1 | ABBVIE INC. | $100.00 | 06/03/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202488073 |
| Principal investigator 1 | Bavarian Nordic A/S | $6,527.40 | 05/16/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214682 |
| Principal investigator 1 | IBSA Institut Biochimique SA | $2,800.00 | 05/14/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH, LLC | A multi-center, prospective, randomized, double-blind, flexible-dose, placebo-controlled, parallel group clinical trial of Sildenafil oral film 25 mg, 50 mg, 75 mg and 100 mg for the treatment of erectile dysfunction (ED) | No dispute reported | 06/30/2026 | 1223438825 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $11,990.30 | 05/09/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research,llc | A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). | No dispute reported | 06/30/2026 | 1226113668 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,186.50 | 05/06/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research,llc | A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). | No dispute reported | 06/30/2026 | 1226113489 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $504.00 | 05/06/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research,llc | A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). | No dispute reported | 06/30/2026 | 1226113495 |
| Principal investigator 1 | Bavarian Nordic A/S | $494.00 | 04/25/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214676 |
| Principal investigator 1 | Bavarian Nordic A/S | $6,935.76 | 04/18/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214652 |
| Principal investigator 1 | Bavarian Nordic A/S | $16,863.19 | 04/01/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214640 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,639.97 | 04/01/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A PHASE 3, FOLLOW-UP TRIAL TO EVALUATE LONG-TERM SAFETY AND ANTIBODY PERSISTENCE, AND THE IMPACT OF A BOOSTER DOSE OF A TETRAVALENT DENGUE VACCINE CANDIDATE IN HEALTHY ADOLESCENTS AND ADULTS IN AREAS NON-ENDEMIC FOR DENGUE | No dispute reported | 06/30/2026 | 1223277312 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $4,536.00 | 03/25/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research,llc | A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). | No dispute reported | 06/30/2026 | 1226113350 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $14,633.50 | 03/25/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research,llc | A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). | No dispute reported | 06/30/2026 | 1226113358 |
| Principal investigator 1 | IBSA Institut Biochimique SA | $4,215.43 | 03/20/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH, LLC | A multi-center, prospective, randomized, double-blind, flexible-dose, placebo-controlled, parallel group clinical trial of Sildenafil oral film 25 mg, 50 mg, 75 mg and 100 mg for the treatment of erectile dysfunction (ED) | No dispute reported | 06/30/2026 | 1223439031 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $3,234.00 | 03/12/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research, LLC, Knoxville | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215517745 |
| Principal investigator 1 | Amgen Inc. | $74,206.00 | 03/05/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARITIME-2) | No dispute reported | 06/30/2026 | 1246639033 |
| Principal investigator 1 | Bavarian Nordic A/S | $4,461.63 | 03/03/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214602 |
| Principal investigator 1 | Amgen Inc. | $309,722.46 | 02/25/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | No dispute reported | 06/30/2026 | 1246639049 |
| Principal investigator 1 | Eli Lilly and Company | $172.75 | 02/20/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLS | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | No dispute reported | 06/30/2026 | 1187871559 |
| Principal investigator 1 | Bavarian Nordic A/S | $133.00 | 02/14/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214614 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $27,741.15 | 02/12/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH | a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older | No dispute reported | 06/30/2026 | 1185540679 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,594.00 | 02/06/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARC H LLC | A Phase 3 Randomized Double-blind Controlled Study to Evaluate the Immunogenicity, Safety, and Reactogenicity of ExPEC9V and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older | No dispute reported | 06/30/2026 | 1175400723 |
| Principal investigator 1 | Eli Lilly and Company | $428.24 | 01/31/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLS | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | No dispute reported | 06/30/2026 | 1187880537 |
| Principal investigator 1 | IBSA Institut Biochimique SA | $1,915.44 | 01/23/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH, LLC | A multi-center, prospective, randomized, double-blind, flexible-dose, placebo-controlled, parallel group clinical trial of Sildenafil oral film 25 mg, 50 mg, 75 mg and 100 mg for the treatment of erectile dysfunction (ED) | No dispute reported | 06/30/2026 | 1223438703 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $27,930.70 | 01/22/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research,llc | A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). | No dispute reported | 06/30/2026 | 1226113244 |
| Principal investigator 1 | Eli Lilly and Company | $19,703.53 | 01/13/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLS | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | No dispute reported | 06/30/2026 | 1187875957 |
| Principal investigator 1 | Eli Lilly and Company | $107,503.00 | 01/07/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLS | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | No dispute reported | 06/30/2026 | 1187876285 |